The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder - A European Multicenter Study

European Neuropsychopharmacology

Volumn 22, Issue 4, 2012, Pages 259-266

  Schosser, A ^a   Calati, R ^b   Serretti, A ^b   Massat, I ^c   A Kocabas, N ^c,d   Papageorgiou, K ^a   Linotte, S ^c   Mendlewicz, J ^c   Souery, D ^c   Zohar, J ^e   Juven Wetzler, A ^e   Montgomery, S ^f   Kasper, S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d GAZI UNIVERSITY   (Turkey)

^e SHEBA MEDICAL CENTER   (Israel)

^f UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Association; COMT; Depression; Pharmacogenetic; Suicidality; Treatment response

Indexed keywords

ANTIDEPRESSANT AGENT; CATECHOL METHYLTRANSFERASE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; SUICIDAL BEHAVIOR; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; CATECHOL O-METHYLTRANSFERASE; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; SUICIDE; SUICIDE, ATTEMPTED;

EID: 84857237350     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.08.007     Document Type: Article

References (43)

1. Arias B., Serretti A., Lorenzi C., Gasto C., Catalan R., Fananas L. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J. Affect. Disord. 2006, 90:251-256.
2. Arsenault-Lapierre G., Kim C., Turecki G. Psychiatric diagnoses in 3275 suicides: a meta-analysis. BMC Psychiatry Nov 2004, 4. ArtID 37.11.
3. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
4. Baune B.T., Hohoff C., Berger K., Neumann A., Mortensen S., Roehrs T., et al. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacol. 2008, 33:924-932.
5. Benjamini Y., Drai D., Elmer G., Kafkafi N., Golani I. Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 2001, 125:279-284.
6. Calati R., Porcelli S., Giegling I., Hartmann A.M., Möller H.J., De Ronchi D., et al. Catechol-o-methyltransferase gene modulation o suicidal behavior and personality traits: a review, meta-analysis and association study. J. Psychiatr. Res. 2011, 45:309-321.
7. Cusin C., Serretti A., Lattuada E., Lilli R., Lorenzi C., Smeraldi E. Association study of MAO-A, COMT, 5-HT2A, DRD2, and DRD4 polymorphisms with illness time course in mood disorders. Am. J. Med. Genet. 2002, 114:380-390.
8. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet. Epidemiol. 2003, 25:115-121.
9. Dupont W.D., Plummer W.D. Power and sample-size calculations - a review and computer-program. Control. Clin. Trials 1990, 11(2):116-128.
10. Frisch A., Postilnick D., Rockah R., Michaelovsky E., Postilnick S., Birman E., et al. Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways. Mol. Psychiatry. 1999, 4:389-392.
11. Fu Q., Heath A.C., Bucholz K.K., Nelson E.C., Glowinski A.L., et al. A twin study of genetic and environmental influences on suicidality in men. Psychol. Med. 2002, 32:11-24.
12. Funke B., Malhotra A.K., Finn C.T., Plocik A.M., Lake S.L., Lencz T., et al. COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav. Brain. Funct. 2005, 1:19.
13. Halleland H., Lindervold A.J., Halmoy A., Haavik J., Johansson S. Association between Catechol O-methyltransferase (COMT) haplotypes and severity of hyperactivity symptoms in Adults. Am. J. Med. Genet. Part B 2009, 150:403-410.
14. Hosak L. Role of COMT gene Val158Met polymorphism in mental disorders: a review. Eur. Psychiatry 2007, 22:276-281.
15. Ising M., Lucae S., Binder E.B., Bettecken T., Uhr M., Ripke S., et al. A genome wide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry. 2009, 66:966-975.
16. Ji Y., Biernacka J., Snyder K., Drews M., Pelleymounter L.L., Colby C., et al. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. Pharmacogenomics 2010, 28. Epub ahead of print.
17. Kia-Keating B.M., Glatt S.J., Tsuang M.T. Meta-analyses suggest association between COMT, but not HTR1B, alleles, and suicidal behavior. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B(8):1048-1053.
18. Kocabas N.A., Faghel C., Barreto M., Kasper S., Linotte S., Mendlewicz J., et al. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. Int. Clin. Psychopharmacol. 2010, 25(4):218-227.
19. Kunugi H., Vallada H.P., Hoda F., Kirov G., Gill M., Aitchison K.J., et al. No evidence for an association of affective disorders with high- or low-activity allele of catechol-O-methyltransferase gene. Biol. Psychiatry 1997, 42:282-285.
20. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M., et al. Human Catechol O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenet. 1996, 6:243-250.
21. Laje G., Paddock S., Manji H., Rush A.J., Wilson A.F., Charney D., et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am. J. Psychiatry 2007, 164:1530-1538.
22. Laje G., Allen A.S., Akula N., Manji H., John Rush A., McMahon F.J. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet. Genomics 2009, 19(9):666-674.
23. Massat I., Souery D., Del-Favero J., Nothen M., Blackwood D., Muir W., et al. Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Mol. Psychiatry. 2005, 10:598-605.
24. Massat I., Kocabas N.A., Crisafulli C., Chiesa A., Calati R., Linotte S., et al. COMT and age at onset in mood disorders: a replication and extension study. Neurosci. Lett. 2011, May 11.
25. McGuffin P., Marusic A., Farmer A. What can psychiatric genetics offer suicidology?. Crisis 2001, 22:61-65.
26. Michaelovsky E., Gothelf D., Korostishevsky M., Frisch A., Burg M., Carmel M., et al. Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS. Int. J. Neuropsychopharmacol. 2007, 11:351-363.
27. Mier D., Kirsch P., Meyer-Lindenberg A.M. Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis. Mol. Psychiatry. 2009, 1-10.
28. Mulder R.T., Joyce P.R., Frampton C.M.A., Luty S.E., Sullivan P.F. Six months of treatment for depression: outcome and predictors of course of illness. Am. J. Psychiatry. 2006, 166:95-100.
29. Nelson J.C., Delucchi K., Schneider L. Suicidal thinking and behavior during treatment with sertraline in late-life depression. Am. J. Geriatr. Psychiatry 2007, 15:573-580.
30. Ohara K., Nagai M., Suzuki Y., Ohara K. Low activity allele of catechol-O-methyltransferase gene and Japanese unipolar depression. Neuroreport 1998, 9:1305-1308.
31. Perlis R.H., Beasley C.M., Wines J.D., Tamura R.N., Cusin C., Shear D., et al. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother. Psychosom. 2007, 76:40-46.
32. Perlis R.H., Purcell S., Fava M., Fagerness J., Rush A.J., Trivedi M.H., et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch. Gen. Psychiatry 2007, 64:689-697.
33. Roy A., Segal N.L., Centerwall B.S., Robinette C.D. Suicide in twins. Arch. Gen. Psychiatry 1991, 48:29-32.
34. Ruhé H.G., van Rooijen G., Spijker J., Peeters F.P., Schene A.H. Staging methods for treatment resistant depression. A systematic review. J. Affect. Disord. 2011, 22. Epub ahead of print.
35. Serretti A., Cusin C., Cristina S., Lorenzi C., Lilli R., Lattuada E., et al. Multicentre Italian family-based association study on tyrosine hydroxylase, catechol-O-methyl transferase, catechol-O-methyl transferase and Wolfram syndrome 1 polymorphisms in mood disorders. Psychiatr. Genet. 2003, 13:121-126.
36. Shield A.J., Thomae B.A., Eckloff B.W., Wieben E.D., Weinshilboum R.M. Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol. Psychiatry 2004, 9:151-160.
37. Shifman S., Bronstein M., Sternfeld M., Pisante-Shalom A., Lev-Lehman E., Weinzman A., et al. A highly significant association between a COMT haplotype and schizophrenia. Am. J. Hum. Genet. 2002, 71:1296-1302.
38. Souery D., Oswald P., Massat I., Bailer U., Bollen J., Demyttenaere K., et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J. Clin. Psychiatry 2007, 68:1062-1070.
39. Suominen K., Isometsa E., Suokas J., Haukka J., Achte K., et al. Completed suicide after a suicide attempt: a 37-year follow-up study. Am. J. Psychiatry 2004, 161:562-563.
40. Szanto K., Mulsant B.H., Houck P.R., Dew M.A., Dombrovski A., Pollock B.G., Reynolds C.F. Emergence, persistence, and resolution of suicidal ideation during treatment of depression in old age. J. Affect. Disord. 2007, 98:153-161.
41. Szegedi A., Rujescu D., Tadic A., Müller M.J., Kohnen R., Stassen H.H., et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 2005, 5:49-53.
42. Wittchen Epidemiology of affective disorders. Contemporary Psychiatry (Vol 3) 2000, 231-241. Springer, Heidelberg. H. Helmchen, F. Henn, H. Lauter, N. Sartorius (Eds.).
43. World Health Organization World Health Report 2000. Health Systems: Improving Performance 2000, World Health Organization, Geneva.